Citigroup reiterates buy on Mirati Therapeutics (MRTX) doubling the price target to $16. CIBC and Cann initiate coverage with outperform rating and target of $18. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.
This author has yet to write their bio.Meanwhile lets just say that we are proud SM contributed a whooping 83 entries.
Entries by SM
Cann and Oppenheimer Holdings reiterate buy on Epizyme (EPZM) with price target of $26. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.
Ipsen’s (IPSEY) Xarmelo approved in EU for carcinoid syndrome diarrhea. Read the detail in our Daily Pharma Scoop at SeekingAlpha Marketplace.
Our daily analysis of a stock with a major event/upside: Geron’s potential with Imetelstat and its agonizingly slow progress towards the market Geron (GERN) imetelstat can potentially bring about a paradigm shift in non-solid cancer therapeutics. Imet inhibits telomerase, an enzyme that enables malignant cells to replicate with its DNA intact by protecting the ends […]
FDA approves Amgen and Allergan's MVASI™ (bevacizumab-awwb) for the treatment of five types of cancer. Approval based on totality of evidence from global development program showing MVASI™ is highly similar to Avastin® (bevacizumab). First ever biosimilar to fight cancer approved by FDA. Full catalyst rundown available in our daily pharma scoop at SeekingAlpha Marketplace page.
Supernus Pharmaceuticals (SUPN) came out with good interim data from a phase 3 study of SPN-810 for the treatment of impulsive aggression (IA) in children 6 - 12 years old. More news in our daily pharma scoop in our SeekingAlpha Marketplace page.
Insider Purchases Ticker Company Insider Title Value Traded AGN Allergan Plc COB, Pres, CEO +$20,626 CASI Casi Pharmaceuticals, Inc. Dir +$419,178 EPZM Epizyme, Inc. Dir +$3,050,000 IRIX Iridex Corp COB, CEO +$16,956 LXRX Lexicon Pharmaceuticals, Inc. Pres, CEO +$376,337 LXRX Lexicon Pharmaceuticals, Inc. Dir +$12,500 NBRV Nabriva Therapeutics Plc 10% +$497,889 OPK Opko Health, Inc. […]
Codexis Inc (CDXS) 10% insider sells $6,121,500. Check out the full insider sales scoop in our daily pharma scoop at our SeekingAlpha Marketplace page.
Wedbush Reiterates Outperform on Nabriva Therapeutics AG (NBRV) raising target from $13 to $21. SunTrust Banks Raises Target from $20 to $24. Cantor Fitzgerald Reiterates Overweight with target of $16. Leerink Swann Reiterates Outperform raising target from $20 to $22. Check out more ratings on our SeekingAlpha Marketplace page.